Cel Sci (CVM) Assets Average (2011 - 2026)
Cel Sci (CVM) posted Assets Average of $20.3 million for Q1 2026, down 20.47% sequentially from $25.5 million in Q4 2025, and down 14.53% YoY from $23.8 million in Q1 2025.
Cel Sci (CVM) Assets Average (2011 - 2026) Analysis & Trends
Cel Sci has reported Assets Average for 14 years, with the latest figure at $20.3 million in Q1 2026.
- Quarterly Assets Average fell 14.53% year-over-year to $20.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.3 million (down 14.53% YoY) and the FY2025 annual result came in at $27.6 million, down 4.12% from the prior year.
- Assets Average declined to $20.3 million in Q1 2026 per CVM's latest filing, from $25.5 million in the prior quarter.
- Over five years, Assets Average peaked at $66.9 million in Q1 2022 and troughed at $20.3 million in Q1 2026.
- A 5-year average of $34.7 million and a median of $29.4 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2023: Assets Average surged 36.59% in 2022, then slumped 41.75% in 2023.
- Over 5 years, Assets Average stood at $47.5 million in 2022, then sank by 37.7% to $29.6 million in 2023, then declined by 11.05% to $26.3 million in 2024, then retreated by 3.11% to $25.5 million in 2025, then decreased by 20.47% to $20.3 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $20.3 million, $25.5 million, and $24.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.61 Bn | 131.75 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.28 Bn | 60.09 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.14 Bn | 54.00 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.83 Bn | 28.52 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 19.82 Bn |
| 10 | Cel Sci | 2.21 Mn | -4.33 Mn | - | 19.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.30 Mn |
| Dec 31, 2025 | 25.53 Mn |
| Sep 30, 2025 | 24.25 Mn |
| Jun 30, 2025 | 21.07 Mn |
| Mar 31, 2025 | 23.75 Mn |
| Dec 31, 2024 | 26.35 Mn |
| Sep 30, 2024 | 25.53 Mn |
| Jun 30, 2024 | 27.06 Mn |
| Mar 31, 2024 | 29.38 Mn |
| Dec 31, 2023 | 29.62 Mn |
| Sep 30, 2023 | 31.42 Mn |
| Jun 30, 2023 | 35.26 Mn |
| Mar 31, 2023 | 41.38 Mn |
| Dec 31, 2022 | 47.54 Mn |
| Sep 30, 2022 | 53.71 Mn |
| Jun 30, 2022 | 60.53 Mn |
| Mar 31, 2022 | 66.92 Mn |
| Dec 31, 2021 | 72.77 Mn |
| Sep 30, 2021 | 77.76 Mn |
| Jun 30, 2021 | 64.00 Mn |